Natco Pharma gets EIR from USFDA for Kothur facility

Published On 2016-08-17 06:03 GMT   |   Update On 2016-08-17 06:03 GMT

New Delhi : Drug firm Natco Pharma said it has received Establishment Inspection Report (EIR) for its Kothur facility in Telangana from the US health regulator after successful completion of inspection.


"Natco Pharma is pleased to announce successful EIR from the US Food and Drug Administration (USFDA) for the inspection conducted at its drug manufacturing facility in Kothur Village, Mahaboob Nagar District, during the period February 29 - March 7, 2016," the company said in a BSE filing.


"The Kothur facility predominantly caters to regulated international markets, including USA," it added.


EIR is given to an establishment after the completion of the inspection by the USFDA.


Natco Pharma shares were trading 1.10 per cent higher at Rs 641 on BSE in afternoon session.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News